cemiplimab + carboplatin + docetaxel

This combination consists of three agents: - **Cemiplimab**: a human monoclonal antibody that targets the programmed cell death-1 (PD-1) receptor, thereby blocking PD-1-mediated immune checkpoint inhibition and allowing the immune system to attack tumor cells. - **Carboplatin**: a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis, primarily acting as a cytotoxic antineoplastic. - **Docetaxel**: a taxane chemotherapy that promotes and stabilizes microtubule assembly, thereby inhibiting cell division and inducing apoptosis in rapidly dividing tumor cells. The combination is being investigated in clinical trials, particularly as a **neoadjuvant regimen for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) and advanced/metastatic cancers**. Use of cemiplimab (immunotherapy) with platinum-doublet chemotherapy (carboplatin + docetaxel) aims to augment anti-tumor immune response and achieve superior clinical/pathological responses compared to chemotherapy alone[7][5][1].